TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer

• Status: Not yet recruiting
• Trial end date: 2024-02-28
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the clinical efficacy and safety of TAS-102 combined with bevacizumab and tislelizumab in third-line or above treatment in patients with advanced colorectal adenocarcinoma with liver metastasis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fujian Cancer Hospital
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Patients who provided informed consent and voluntarily enrolled

• Patients with liver metastasis of advanced colorectal adenocarcinoma with MSS confirmed by pathology;

• 18-75 years old;

• Measurable target lesions according to RECIST V1.1 assessment criteria;

• Progression after standard second-line treatment (irinotecan, oxaliplatin, or fluorouracil);

• 0 ~ 2 points according to ECOG quality of life score;

• Drugs can be taken orally

• Estimated survival ≥3 months;

• Women of childbearing age should comply with contraceptive measures if pregnancy test is negative;

• Ascites with no obvious symptoms and no clinical intervention;

• Adequate organ and bone marrow functions, ecg, blood, biochemical and other basic tests are not contraindications of chemotherapy;

• Adherence to scheduled visits, treatment plans, laboratory tests, and other study procedures Willingness and ability.

Exclusion Criteria:

• Previous application of TAS-102;

• Pregnant or lactating women;

• No contraception during the reproductive period;

• patients known to have a history of allergy to any study drug, similar drug or excipient;

• Patients with risk of massive gastrointestinal bleeding or gastrointestinal obstruction;

• Patients with a history of thromboembolism, except those caused by PICC;

• Patients with active infection;

• Patients with uncontrolled hypertension (systolic blood pressure ≥160 mmHg and diastolic blood pressure ≥90) MmHg);

• Patients with brain metastases with clinical symptoms or imaging evidence;

• Contraindications for treatment of other chronic diseases;

• Previous immunotherapy-related myocarditis, pneumonia, colitis, hepatitis, kidney Inflammation and other conditions, the current AE is still ≥2;

• According to THE NCI CTCAE 5.0 assessment criteria, there are all types of existing cases due to previous treatment Patients with grade ≥2 toxic reactions;

• Other conditions that the investigator determines are not suitable for inclusion in the study.

• Received any anti-tumor therapy and participated in other clinical studies within 4 weeks prior to enrollment.